HLA Fine Mapping to Elucidate S. aureus Susceptibility
HLA Fine Mapping to Elucidate S. aureus Susceptibility
批准号:
10490895
负责人:
Vance G. Fowler
金额:
$78.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-17 至 2026-08-31
关键词:
AdmixtureAfrican AmericanAllelesAntigen-Presenting CellsAntigenic VariationBacteremiaBacteriaBacterial InfectionsBiologicalBiological ModelsBiological ProcessBlood CirculationCollectionEndocarditisEnrollmentEuropeanFrequenciesGeneticGenetic DeterminismGenetic VariationGenotypeGoalsHLA AntigensHaplotypesHistocompatibility Antigens Class IIHumanImmune responseIn VitroIndividualInfectionLinkMedicalModelingMulti-Drug ResistanceNucleotidesOsteomyelitisPatientsPredispositionPreventionProspective cohortProteinsPublic HealthResearch PersonnelResourcesRiskSamplingSepsisSeveritiesSoft Tissue InfectionsStaphylococcus aureusStaphylococcus aureus infectionStreptococcus pyogenesSuperantigensT cell responseT-LymphocyteTestingTransgenic MiceUnited StatesVariantWorkbasebiobankclinically relevantcohortdeep sequencingdensityexperienceexperimental studygenetic risk factorgenetic variantgenome wide association studygenome-widegenotyping technologyhuman DNAimprovedin vivoin vivo Modelinnovationmethicillin resistant Staphylococcus aureusmulti-ethnicmultidisciplinaryprospective
中文摘要
这个应用程序使用一个大的人类前瞻性队列来确定宿主的遗传决定因素
英文摘要
This application uses a large human prospective cohort to identify the host genetic determinants of
susceptibility to Staphylococcus aureus bacteremia (SAB), a common and potentially lethal infection. The
overarching hypothesis to be tested in this study is that specific variants in the Human Leukocyte Antigen
(HLA) class II region are important determinants of susceptibility to SAB in humans, and that these
determinants can be identified by studying large, well-characterized cohorts of patients. This hypothesis is
based upon our two separate studies that 1) identified genome-wide significant associations of variants in HLA
class II with an increased risk for S. aureus infections in individuals of European descent; and 2) identified a
genome-wide association of European-derived HLA Class II variants and SAB in African-American patients. In
the proposed study, we will further refine the genetic risk factors for SAB in the HLA class II region. We created
the S. aureus Bacteremia Group (SABG), one of the world’s largest collections of paired human DNA and
bloodstream bacteria from patients with SAB. We assembled an experienced multidisciplinary team to link the
unique SABG cohort resources to state-of-the-art genotyping technology and innovative in vivo model systems,
pushing the boundaries of the field. We propose three Specific Aims. In Aim 1, we will identify the genetic risk
factors in HLA class II for developing SAB, using high-density genotyping and imputation to saturate the HLA
region in 2300 individuals with SAB and 2300 unaffected controls enrolled in the longitudinal, prospective
SABG cohort. In Aim 2, we will examine the association of HLA class II alleles and haplotypes with
complicated SAB in the 2300 patients with SAB genotyped in SA1, and consider the impact of bacterial
genotype on the risk for complicated SAB by genotyping the bloodstream S. aureus isolates from all of the
2300 SAB patients. In this way, we will test whether the association of complicated SAB with HLA class II
alleles and haplotypes is modified by the specific genetic lineage of the bloodstream S. aureus. In Aim 3, we
will evaluate the functional consequences of the HLA alleles identified in Aim 1, Aim 2, and in our previous
studies with in vivo and in vitro experiments. We will evaluate whether specific HLA class II alleles significantly
alter host T cell responses to S. aureus using 1) a S. aureus sepsis model in transgenic mice expressing
human HLA class II alleles; and 2) stimulation of T cells from SAB patients using S. aureus infected antigen
presenting cells expressing different HLA alleles. The long-term objectives of this project are 1) to fully
characterize HLA variation in a multi-ethnic sample of individuals with SAB and unaffected controls; and 2) to
provide biological evidence for the clinical relevance of the HLA class II variants identified in this project. Taken
together, the impact of this proposal is to increase our understanding of how host genetic variation influences
the initiation and severity of S. aureus infections. Elucidating the genetic basis of susceptibility to S. aureus
infection will improve our understanding, treatment, and prevention of this urgent unmet medical crisis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HLA Fine Mapping to Elucidate S. aureus Susceptibility
-
批准号:10344003
-
项目类别:
-
资助金额:$80.7万
-
财政年份:2021
-
负责人:Vance G. Fowler
-
依托单位:
2013 Staphylococcal Diseases Gordon Research Conference and Gordon Research Semin
-
批准号:8526118
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
Antibacterial Resistance Leadership Group (ARLG)
-
批准号:10064119
-
项目类别:
-
资助金额:$1970.99万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
Antibacterial Resistance Leadership Group (ARLG)
-
批准号:10247231
-
项目类别:
-
资助金额:$5.64万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
Antibacterial Resistance Leadership Group (ARLG)
-
批准号:8667988
-
项目类别:
-
资助金额:$1300.0万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
Antibacterial Resistance Leadership Group (ARLG)
-
批准号:8776915
-
项目类别:
-
资助金额:$1128.63万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
Antibacterial Resistance Leadership Group (ARLG)
-
批准号:10308017
-
项目类别:
-
资助金额:$1472.99万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
Antibacterial Resistance Leadership Group (ARLG)
-
批准号:8478367
-
项目类别:
-
资助金额:$200.0万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
Antibacterial Resistance Leadership Group (ARLG)
-
批准号:8975602
-
项目类别:
-
资助金额:$1000.0万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
Antibacterial Resistance Leadership Group (ARLG)
-
批准号:10542803
-
项目类别:
-
资助金额:$1467.56万
-
财政年份:2013
-
负责人:Vance G. Fowler
-
依托单位:
2011 Staphyloccocal Diseases Gordon Research Conference
-
批准号:8193559
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2011
-
负责人:Vance G. Fowler
-
依托单位:
Mentoring Clinical and Translational Patient-Oriented Research in Staphylococci
-
批准号:8606149
-
项目类别:
-
资助金额:$13.88万
-
财政年份:2011
-
负责人:Vance G. Fowler
-
依托单位:
Mentoring Clinical and Translational Patient-Oriented Research in Staphylococci
-
批准号:8233974
-
项目类别:
-
资助金额:$14.04万
-
财政年份:2011
-
负责人:Vance G. Fowler
-
依托单位:
Mentoring Clinical and Translational Patient-Oriented Research in Staphylococci
-
批准号:8429506
-
项目类别:
-
资助金额:$13.97万
-
财政年份:2011
-
负责人:Vance G. Fowler
-
依托单位:
Mentoring Clinical and Translational Patient-Oriented Research in Staphylococci
-
批准号:8091482
-
项目类别:
-
资助金额:$14.12万
-
财政年份:2011
-
负责人:Vance G. Fowler
-
依托单位:
Mentoring Clinical and Translational Patient-Oriented Research in Staphylococci
-
批准号:8806504
-
项目类别:
-
资助金额:$13.8万
-
财政年份:2011
-
负责人:Vance G. Fowler
-
依托单位:
Host Susceptibility to S. aureus
-
批准号:8462886
-
项目类别:
-
资助金额:$66.28万
-
财政年份:2007
-
负责人:Vance G. Fowler
-
依托单位:
Host Susceptibility to S. aureus
-
批准号:8371911
-
项目类别:
-
资助金额:$71.51万
-
财政年份:2007
-
负责人:Vance G. Fowler
-
依托单位:
Host Susceptibility S. aureus
-
批准号:7208439
-
项目类别:
-
资助金额:$60.66万
-
财政年份:2007
-
负责人:Vance G. Fowler
-
依托单位:
Host Susceptibility S. aureus
-
批准号:7373622
-
项目类别:
-
资助金额:$84.76万
-
财政年份:2007
-
负责人:Vance G. Fowler
-
依托单位:
海外基金